Q-omics provides the consensus-scored PIMREGP2 profile across patient tissues and cancer cell-line models. PIMREGP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PIMREGP2 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, PIMREGP2 RNA expression shows 9,681 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCEC, LUSC, and LIHC as cancer lineages where PIMREGP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIMREGP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIMREGP2 survival associations across molecular data types. PIMREGP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIMREGP2 RNA expression–survival associations across cancer types. High PIMREGP2 expression shows unfavorable associations in UCEC, SKCM, LIHC and KIRC, but favorable associations in HNSC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for PIMREGP2 RNA expression.
This table summarizes PIMREGP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PIMREGP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIMREGP2 shows lower tumor expression in LUSC and KIRC and higher tumor expression in STAD, BRCA, PRAD and CHOL. The LUSC box plot shows higher PIMREGP2 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p < 0.001).
This table shows molecular features associated with PIMREGP2 in patient tissues and cancer cell lines. In patient samples, PIMREGP2 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
